Demonstrates increased penile length in a male infant with partial androgen insensitivity syndrome, indicating a promising hormonal intervention.
The optimal approach to hormonal treatment aimed at increasing penis size has been established for infant males with micropenis; however, data are limited in partial androgen insensitivity syndrome (PAIS). We report a 6-month-old male patient treated with intramuscular testosterone for micropenis. At birth, he presented with atypical genitalia, including a microphallus, hypospadias, and a bifid scrotum. His karyotype was 46,XY, and endocrine evaluation revealed normal testicular function. A novel missense variant of the AR gene (p.G578E) was identified. Intramuscular testosterone enanthate 62.5 mg/dose was administered every 4 weeks for 3 doses (6-8 months). Stretched penile length increased from 18 to 30 mm (+67%) without adverse events. During treatment, luteinizing hormone secretion was suppressed, with trough levels falling below the limit of detection, consistent with androgen-mediated negative feedback. Luteinizing hormone levels during mini-puberty in response to testosterone treatment, supporting testosterone therapy in patients with PAIS.
No takes yet. Share an insight, caveat, or question.
Shuto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: